Q2 2026 saw a sharp year-over-year decline in earnings and revenue, driven by lower membership and higher medical costs, but operating cash flow improved. Full year adjusted EPS guidance was raised to at least $5.25, with Medicaid and Medicare segments performing in line or better than expectations…
Q2 2026 saw a sharp year-over-year decline in earnings and revenue, driven by lower membership and higher medical costs, but operating cash flow improved. Full year adjusted EPS guidance was raised to at least $5.25, with Medicaid and Medicare segments performing in line or better than expectations.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
